Adaptive Biotechnologies Corp
NASDAQ:ADPT
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Price:
2.6 USD
-0.38%
Market Closed
Updated:
Apr 29, 2024
Adaptive Biotechnologies Corp
Cost of Revenue
|
Adaptive Biotechnologies Corp
Cost of Revenue Peer Comparison
Comparables:
TMO
DHR
MTD
A
IQV
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
Cost of Revenue
-$75.6m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cost of Revenue
-$25.8B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-13%
|
|
|
Danaher Corp
NYSE:DHR
|
Cost of Revenue
-$18.2B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-7%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cost of Revenue
-$1.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cost of Revenue
-$3.3B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cost of Revenue
-$9.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
See Also
What is Adaptive Biotechnologies Corp's Cost of Revenue?
Cost of Revenue
-75.6m
USD
-75.6m
USD
Based on the financial report for Dec 31, 2023, Adaptive Biotechnologies Corp's Cost of Revenue amounts to -75.6m USD.
What is Adaptive Biotechnologies Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-31%
-31%
Over the last year, the Cost of Revenue growth was -30%. The average annual Cost of Revenue growth rates for Adaptive Biotechnologies Corp have been -50% over the past three years , -31% over the past five years .
You don't have any saved screeners yet
